

Press Release

Daiichi Sankyo Announces Changes to its Global Management Structure and Managing Director of Daiichi Sankyo Europe GmbH

Tokyo, Japan - (September 8, 2023) – Daiichi Sankyo Company, Limited, today announced changes to its Global Management Structure and to the Managing Director of Daiichi Sankyo Europe GmbH.

1. Change to the Global Management Structure (Effective from October 1, 2023)

Name	Current Responsibility*	New Responsibility*
Oliver Appelhans	Head of Commercial Operations, EU Specialty Business Unit	Head of EU Specialty Business Unit

* Responsibility under Global Management Structure

† Dr. Jan Van Ruymbeke is scheduled to retire as the Head of EU Specialty Business Unit on September 30, 2023

2. Change to the Managing Director at Daiichi Sankyo Europe GmbH (Effective from November 1, 2023)

Name	Current Responsibility	New Responsibility
Masahiro Kato	Principal, Sustainability Promotion Department, Daiichi Sankyo Company, Limited	Managing Director, Daiichi Sankyo Europe GmbH

† Dr. Jan Van Ruymbeke is scheduled to retire as the Managing Director of Daiichi Sankyo Europe GmbH on March 31, 2024

Reference: Global Management Structure as of October 1, 2023.

CEO•COO

Name	Responsibility*
Sunao Manabe	Chief Executive Officer
Hiroyuki Okuzawa	Chief Operating Officer

Global Corporate Function

Name	Responsibility*
Takashi Fukuoka	Head of Global Corporate Strategy, Chief Strategy Officer
Stuart Mackey	Head of Global Business Development
Koji Ogawa	Head of Global Corporate Planning & Management, Chief Financial Officer
Masahiko Ohtsuki	Head of Global DX, Chief Digital Transformation Officer
Takashi Matsumoto	Head of Global HR, Chief Human Resources Officer
Naoto Tsukaguchi	Head of Global Legal & IP, General Counsel
Naoto Tsukaguchi	Head of Global Compliance & Risk

Business Units

Name	Responsibility*
Shoji Hirashima	Head of Japan Business Unit
Ken Keller	Head of Oncology Business Unit
Oliver Appelhans	Head of EU Specialty Business Unit
Kiminori Nagao	Head of ASCA Business Unit
Paul Diolosa	Head of American Regent Unit
Katsuhiko Yoshida	Head of Daiichi Sankyo Healthcare Unit

Functional Units

Name	Responsibility*
Ken Takeshita	Head of Research & Development Unit
Hiroto Kashiwase	Head of Technology Unit
Toshinobu Taki	Head of Quality Assurance & Regulatory Affairs Unit
Kento Wada	Head of Clinical Safety & Pharmacovigilance Unit

Internal Audit

Name	Responsibility*
Terumichi Yokoyama	Head of Global Internal Audit

* Responsibility under Global Management Structure

About Daiichi Sankyo

Daiichi Sankyo is an innovative global healthcare company contributing to the sustainable development of society that discovers, develops, and delivers new standards of care to enrich the quality of life around the world. With more than 120 years of experience, Daiichi Sankyo leverages its world-class science and technology to create new modalities and innovative medicines for people with cancer, cardiovascular, and other diseases with high unmet medical need. For more information, please visit www.daiichisankyo.com.

Media Contacts:

Japan:

Koji Ogiwara
Daiichi Sankyo Co., Ltd.
ogiwara.koji.ay@daiichisankyo.co.jp
+81 3 6225 1126 (office)

Investor Relations Contact:

DaiichiSankyoIR@daiichisankyo.co.jp